Dr Reddy's Pumps Complex Generics Play with Teva deal
Executive Summary
Dr. Reddy's Laboratories Ltd. is acquiring a basket of ANDAs from Teva Pharmaceutical Industries Ltd. as it increasingly leans towards developing and building a portfolio of complex and limited competition generics in the US and hopes to become "more relevant" there.
You may also be interested in...
Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe
Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.
'No Meaningful Change' In Pricing Environment, Teva Says
Teva reported a drop in first quarter revenues that was smaller than expected on better sales from its specialty business. CEO Erez Vigodman claims the deal to acquire Allergan's generics business is on track to close in June and will transform Teva into an "even stronger company."
Three-Plant FDA Warning Spooks Dr Reddy's, Clouds ANDAs
Dr Reddy's Laboratories was bludgeoned on Indian bourses after the firm said that it had received FDA warning letters at three manufacturing sites, including an oncology plant, in India.